Oncogene PRR14 promotes breast cancer through activation of PI3K signal pathway and inhibition of CHEK2 pathway
Nuclear envelope component PRR14 has been detected to be upregulated in varieties of cancers, especially in breast cancer. But its role in breast carcinogenesis is poorly understood. In this study, we show PRR14 contributes to breast carcinogenesis mainly through overexpression, which derives from elevated transcription and gene amplification. Increased PRR14 expression promotes breast cancer cell proliferation and tumor formation. Biochemical analysis reveals, in addition to previously reported activation of PI3-kinase/Akt/mTOR pathway, PRR14 overexpression regulates cell cycle in breast cancer by inhibiting CHEK2's activation, followed with the deregulation of DNA damage pathway. In correspondence, CHEK2 and PRR14 show opposite impact on breast cancer patients receiving chemotherapy. Collectively, our study is the first to document the oncogenetic role of PRR14 in breast cancer, which protects cells from apoptosis and stimulates proliferation by activating the PI3-kinase/Akt/mTOR pathway and inhibiting the CHEK2 pathway. Both of these pathways are of great influence in breast cancer and PRR14 appears to be their novel interacting node, which renders patients more resistance to chemotherapy and provides a potential therapeutic target in breast cancer.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
---|---|
Enthalten in: |
Cell death & disease - 11(2020), 6 vom: 15. Juni, Seite 464 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ren, Xiaolei [VerfasserIn] |
---|
Links: |
---|
Themen: |
CHEK2 protein, human |
---|
Anmerkungen: |
Date Completed 12.04.2021 Date Revised 15.06.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41419-020-2640-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM311209203 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM311209203 | ||
003 | DE-627 | ||
005 | 20231225141751.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41419-020-2640-8 |2 doi | |
028 | 5 | 2 | |a pubmed24n1037.xml |
035 | |a (DE-627)NLM311209203 | ||
035 | |a (NLM)32541902 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ren, Xiaolei |e verfasserin |4 aut | |
245 | 1 | 0 | |a Oncogene PRR14 promotes breast cancer through activation of PI3K signal pathway and inhibition of CHEK2 pathway |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 12.04.2021 | ||
500 | |a Date Revised 15.06.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Nuclear envelope component PRR14 has been detected to be upregulated in varieties of cancers, especially in breast cancer. But its role in breast carcinogenesis is poorly understood. In this study, we show PRR14 contributes to breast carcinogenesis mainly through overexpression, which derives from elevated transcription and gene amplification. Increased PRR14 expression promotes breast cancer cell proliferation and tumor formation. Biochemical analysis reveals, in addition to previously reported activation of PI3-kinase/Akt/mTOR pathway, PRR14 overexpression regulates cell cycle in breast cancer by inhibiting CHEK2's activation, followed with the deregulation of DNA damage pathway. In correspondence, CHEK2 and PRR14 show opposite impact on breast cancer patients receiving chemotherapy. Collectively, our study is the first to document the oncogenetic role of PRR14 in breast cancer, which protects cells from apoptosis and stimulates proliferation by activating the PI3-kinase/Akt/mTOR pathway and inhibiting the CHEK2 pathway. Both of these pathways are of great influence in breast cancer and PRR14 appears to be their novel interacting node, which renders patients more resistance to chemotherapy and provides a potential therapeutic target in breast cancer | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Chromosomal Proteins, Non-Histone |2 NLM | |
650 | 7 | |a PRR14 protein, human |2 NLM | |
650 | 7 | |a Checkpoint Kinase 2 |2 NLM | |
650 | 7 | |a EC 2.7.1.11 |2 NLM | |
650 | 7 | |a CHEK2 protein, human |2 NLM | |
650 | 7 | |a EC 2.7.11.1 |2 NLM | |
700 | 1 | |a Long, Meijun |e verfasserin |4 aut | |
700 | 1 | |a Li, Zhihong |e verfasserin |4 aut | |
700 | 1 | |a Wu, Boda |e verfasserin |4 aut | |
700 | 1 | |a Jin, Tao |e verfasserin |4 aut | |
700 | 1 | |a Tu, Chao |e verfasserin |4 aut | |
700 | 1 | |a Qi, Lin |e verfasserin |4 aut | |
700 | 1 | |a Yang, Mei |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cell death & disease |d 2010 |g 11(2020), 6 vom: 15. Juni, Seite 464 |w (DE-627)NLM202030881 |x 2041-4889 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2020 |g number:6 |g day:15 |g month:06 |g pages:464 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41419-020-2640-8 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 11 |j 2020 |e 6 |b 15 |c 06 |h 464 |